Daniele Santini

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

Bone health in cancer: ESMO Clinical Practice Guidelines

Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body et al. · Annals of Oncology · 2020 · 518 citations · Full text

Medicine, Oncology, Pharmacology +17

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

Massimo Di Maïo, Ethan Basch, Fabrice Denis et al. · Annals of Oncology · 2022 · 480 citations · Full text

Pharmacy, Oncology, Cancer Rehabilitation +15

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17